Zydus Lifesciences secures FDA tentative approval for Olaparib tablets
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
The antibody was designed and developed at Abzena’s Cambridge, UK,
Subscribe To Our Newsletter & Stay Updated